









Markets
/
Stocks
/
nasdaq-sngx
/

Soligenix Inc

SNGX

1.130USD

+0.090+8.65%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

11.14MMarket Cap

LossP/E TTM



Soligenix Inc

1.130

+0.090+8.65%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Soligenix Inc

Currency: USD Updated: 2026-02-06

Key Insights

Soligenix Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 120 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Soligenix Inc's Score

Industry at a Glance

Industry Ranking

120 / 392

Overall Ranking

256 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Soligenix Inc Highlights

StrengthsRisks

Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).

Growing

The company is in a growing phase, with the latest annual income totaling USD 119.37K.

Overvalued

The company’s latest PE is -0.33, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.46M shares, increasing 44.46% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 85.47K shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

17.500

Target Price

+1408.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Soligenix Inc is 6.59, ranking 237 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.59

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.84

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.69

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.36

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Soligenix Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Soligenix Inc is 8.27, ranking 53 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.33, which is -55.17% below the recent high of -0.15 and -525.08% above the recent low of -2.05.

Score

Industry at a Glance

Previous score

8.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 120/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Soligenix Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 17.50, with a high of 25.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

17.500

Target Price

+1408.62%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Soligenix Inc

SNGX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Soligenix Inc is 5.70, ranking 298 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.39 and the support level at 0.95, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.45

Change

0.25

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.050

Sell

RSI(14)

36.857

Neutral

STOCH(KDJ)(9,3,3)

17.423

Neutral

ATR(14)

0.087

High Vlolatility

CCI(14)

-132.288

Sell

Williams %R

75.000

Sell

TRIX(12,20)

-0.628

Sell

StochRSI(14)

86.516

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.158

Sell

MA10

1.235

Sell

MA20

1.308

Sell

MA50

1.404

Sell

MA100

1.506

Sell

MA200

1.810

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Soligenix Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 14.44%, representing a quarter-over-quarter increase of 399.01%. The largest institutional shareholder is The Vanguard, holding a total of 85.47K shares, representing 0.85% of shares outstanding, with 740.67% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Armistice Capital LLC

708.00K

Intracoastal Capital, L.L.C.

425.00K

DRW Securities, LLC

171.42K

Two Sigma Investments, LP

87.65K

The Vanguard Group, Inc.

Star Investors

52.52K

+2303.75%

Sabby Management, LLC

81.00K

Renaissance Technologies LLC

Star Investors

72.90K

HRT Financial LP

54.67K

Virtu Americas LLC

50.86K

Banco BTG Pactual SA

46.37K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Soligenix Inc is 2.27, ranking 241 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.02. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.